Biotechnology Innovation Organization
@IAmBiotech
Followers
106K
Following
9K
Media
8K
Statuses
38K
I Am Biotech is where biotech professionals and enthusiasts can come together and discuss the promise of biotech innovation. #Biotech
Washington, DC
Joined January 2009
A major investment in U.S. biotech: @Amgen will put more than $600M into a new center for science and innovation at its Thousand Oaks HQ. The state-of-the-art facility will accelerate discovery, fuel cross-disciplinary collaboration, and generate hundreds of new U.S. jobs.
We’re investing in U.S. science and innovation. The new, state-of-the-art Center for Science and Innovation creates hundreds of U.S. jobs at our California headquarters. 🔗 Read more: . $AMGN
0
0
2
#ICYMI #TezcatBiosciences, winner of BIO’s 2025 Start-Up Stadium, is pioneering a novel “Trojan horse” approach to target RAS-driven cancers. Read more from Tezcat's conversation w/ about their innovation journey:
0
4
6
Congratulations to BIO members @eisaiusneuro & @biogen on FDA approval of the first at-home injection for early Alzheimer’s maintenance. This milestone is yet another example of how U.S. biotech is driving innovation that fuels new hope for millions of families. Read more:.
ICYMI: We recently shared an update for our treatment for early Alzheimer’s disease. Learn more.
2
1
0
The Priority Review Voucher program has delivered lifesaving treatments for children who once had none. Congress must reauthorize it now to ignite U.S. innovation and ensure children don’t lose access to cures – and hope. Learn more:
1
2
4
Earlier this week, BIO President & CEO John F. Crowley delivered keynote remarks at the 2025 Georgia Life Sciences Summit in Atlanta. In conversation with @Georgia_Bio CEO Maria Thacker Goethe, he emphasized biotechnology’s power to improve lives, the industry’s growth potential,
5
0
1
Biotech M&A may have slowed, but deals are still happening. Experts say companies with strong data and clear communication are the ones attracting partners, especially in areas like oncology, obesity, and autoimmune disease. Read more on
1
1
1
Psoriasis affects 8 million people in the U.S. and 125 million worldwide. With multiple barriers to treatment, advocates like the National Psoriasis Foundation are working to pass the Safe Step Act to improve access. Read more on
1
0
2
Superbugs are on the rise—and the market for new antibiotics is broken. BIO’s Emily Wheeler highlights the urgent need for policy solutions like the PASTEUR Act to ensure doctors have tools to fight drug-resistant infections. Learn more:
medicaleconomics.com
Legislative solutions can incentivize research and development for lifesaving antimicrobials.
0
3
5
This week marked a big step for #biotech in North Carolina: Genentech broke ground on its first East Coast site in Holly Springs. The $700M investment will drive U.S.-based innovation, grow NC’s biotech ecosystem, and create 1,900+ jobs while advancing next-gen metabolic and.
Today we broke ground on our new $700M facility in Holly Springs, NC—Genentech’s first East Coast site. This 700K-sq-ft hub will support next-gen metabolic medicines and create 1,900+ jobs, strengthening U.S. innovation in biotech.
0
0
6
Driving growth in U.S. innovation and jobs looks like this. @ionispharma has just received FDA approval of the first and only RNA-targeted treatment of hereditary angioedema (HAE). This is a critical advancement for patients and families living with this rare genetic condition.
Today, the U.S. FDA approved our medicine for hereditary angioedema (#HAE), marking a significant and encouraging advance for the community, many of whom continue to live with unpredictable, severe swelling attacks. Hear from our CEO, Brett P. Monia, PhD.
0
0
4
Biotech leaders and patient advocates across the U.S. are urging Congress to make permanent the SBIR and STTR funding programs that grow thousands of small biomanufacturers and deliver breakthroughs for patients across the U.S.
2
1
6
See how the best minds in Phoenix are putting memory testing at the forefront of making brain health more accessible in The Next Frontier, a film series presented for BIO by @BBCStoryWorks. Watch now: . Story produced for @CityofPhoenixAZ | @PHXEconDev
1
0
4
New metabolic drugs are changing weight loss and longevity. Scientists and investors say the next frontier is durability, safety, and access. spoke with Maha Radhakrishnan, M.D., Executive Partner at Sofinnova Investments. Read more on
1
2
10
The Rare Pediatric Disease PRV program has sped up lifesaving treatments for millions of children. Congress must reauthorize it now to ignite U.S. innovation and ensure children don’t lose access to cures – and hope. Learn more:
0
0
4
ICYMI: Fritz Bittenbender, @genentech SVP and BIO’s new Board Chair, shares his vision for advancing biotech, aligning rapid innovation with smart policy and modernizing the FDA through advanced tech and AI. Read more:
1
1
3
For 30+ years, childhood immunizations have saved millions of lives, preventing over 32 million hospitalizations. A stronger America starts with healthy Americans. Learn more:
0
1
6
“Small companies are the lifeblood of the industry and a lot of what they do, and what they’re experiencing, greatly affects the industry as a whole.” BIO's Chad Wessel breaks down our new report that finds early-stage funding for emerging biotechs is scarce. Read more on
0
0
2
The SBIR and STTR invests $4B in thousands of small-medium sized companies each year, driving 12% of all FDA-approved drugs. This bipartisan lifeline for early-stage biotech expires Sept. 30 unless Congress renews it. Read more:
0
0
2